SCHEMBL29901409

SCHEMBL29901409

C=C(C)c1cc(OCC(=O)O)c(F)c(Cl)c1Cc1ccc(O)c(C(C)C)c1

nearest known ligand 0.58

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 20/20 0.58
▸ THRA P10827 19/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23409902 1.00 THRB (0.58) THRBTHRA
SCHEMBL23409841 0.89 THRB (0.46) THRBTHRA
SCHEMBL29901503 0.89 THRB (0.46) THRBTHRA
SCHEMBL29970968 0.88 THRB (0.65) THRBTHRA
SCHEMBL23409511 0.88 THRB (0.65) THRBTHRA
SCHEMBL23409425 0.87 THRB (0.70) THRBTHRA
SCHEMBL29970501 0.87 THRB (0.64) THRBTHRA
SCHEMBL23409503 0.87 THRB (0.64) THRBTHRA
SCHEMBL29971115 0.87 THRB (0.70) THRBTHRA
SCHEMBL23409600 0.86 THRB (0.67) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 — — US disclosed
CN-115279359-A Novel thyromimetic agents 速通医疗公司 2022-11-01 — — CN disclosed
EP-4065098-A1 NOVEL THYROMIMETICS Autobahn Therapeutics, Inc. (US) 2022-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230048992-A1 NOVEL THYROMIMETICS TSHR, TPO, CHRM1 THRB 9/4885THRA 8/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 THRB 9/4885THRA 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback